Welcome to Idorsia

Idorsia announces
financial results for the
first quarter of 2021

Our 2020 report
consists of four
books

Our key assets have
the potential to
transform treatment in
the target indications...

The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients.

Idorsia’s success depends on its people.

Idorsia's development compounds target a number of different diseases.

22 Apr 2021	Idorsia announces financial results for the first quarter 2021 – substantial progress made across the pipeline – launch preparations well underway
01 Apr 2021	Idorsia issues Notice of the 2021 Annual General Meeting of Shareholders
26 Mar 2021	The European Medicines Agency’s CHMP issues a positive opinion recommending marketing authorisation for Ponvory (ponesimod) to treat adults with relapsing forms of multiple sclerosis

Event	When
Annual General Meeting of Shareholders	May 12, 2021
Half-Year 2021 Financial Results reporting*	July 27, 2021
Nine-months 2021 Financial Results reporting*	October 26, 2021
Full-Year 2021 Financial Results reporting*	February 8, 2022

*We will be in a silent period for 10 days ahead of the financial reporting.

IDIA SIX Swiss Exchange

At 17:19:55 CET

23.40 CHF

+0.50 (+2.18 %)

Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91

4123 Allschwil

Switzerland